These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18187580)

  • 21. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences.
    Menendez D; Inga A; Resnick MA
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1500-5. PubMed ID: 20080630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Alu repeats on the evolution of human p53 binding sites.
    Cui F; Sirotin MV; Zhurkin VB
    Biol Direct; 2011 Jan; 6():2. PubMed ID: 21208455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
    Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
    Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reporter gene regulation in Saccharomyces cerevisiae by the human p53 tumor suppressor protein.
    Bitter GA; Schaeffer TN; Ellison AR
    J Mol Microbiol Biotechnol; 2002 Nov; 4(6):539-50. PubMed ID: 12432954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1.
    Menendez D; Inga A; Snipe J; Krysiak O; Schönfelder G; Resnick MA
    Mol Cell Biol; 2007 Apr; 27(7):2590-600. PubMed ID: 17242190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53.
    Kim E; Rohaly G; Heinrichs S; Gimnopoulos D; Meissner H; Deppert W
    Oncogene; 1999 Dec; 18(51):7310-8. PubMed ID: 10602486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptional regulation by p53: one protein, many possibilities.
    Laptenko O; Prives C
    Cell Death Differ; 2006 Jun; 13(6):951-61. PubMed ID: 16575405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression based predictor for p53 transactivation.
    Gowrisankar S; Jegga AG
    BMC Bioinformatics; 2009 Jul; 10():215. PubMed ID: 19602281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm.
    Perez CA; Ott J; Mays DJ; Pietenpol JA
    Oncogene; 2007 Nov; 26(52):7363-70. PubMed ID: 17563751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 Pre- and post-binding event theories revisited: stresses reveal specific and dynamic p53-binding patterns on the p21 gene promoter.
    Millau JF; Bastien N; Bouchard EF; Drouin R
    Cancer Res; 2009 Nov; 69(21):8463-71. PubMed ID: 19843844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.
    Nourani A; Doyon Y; Utley RT; Allard S; Lane WS; Côté J
    Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The structure formed by inverted repeats in p53 response elements determines the transactivation activity of p53 protein.
    Brázda V; Čechová J; Battistin M; Coufal J; Jagelská EB; Raimondi I; Inga A
    Biochem Biophys Res Commun; 2017 Jan; 483(1):516-521. PubMed ID: 28007599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.
    Harmes DC; Bresnick E; Lubin EA; Watson JK; Heim KE; Curtin JC; Suskind AM; Lamb J; DiRenzo J
    Oncogene; 2003 Oct; 22(48):7607-16. PubMed ID: 14576823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
    Inga A; Monti P; Fronza G; Darden T; Resnick MA
    Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expanding universe of p53 targets.
    Menendez D; Inga A; Resnick MA
    Nat Rev Cancer; 2009 Oct; 9(10):724-37. PubMed ID: 19776742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.
    Koutsodontis G; Vasilaki E; Chou WC; Papakosta P; Kardassis D
    Biochem J; 2005 Jul; 389(Pt 2):443-55. PubMed ID: 15790310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The complex architecture of p53 binding sites.
    Senitzki A; Safieh J; Sharma V; Golovenko D; Danin-Poleg Y; Inga A; Haran TE
    Nucleic Acids Res; 2021 Feb; 49(3):1364-1382. PubMed ID: 33444431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A molecular mechanism for the "digital" response of p53 to stress.
    Safieh J; Chazan A; Saleem H; Vyas P; Danin-Poleg Y; Ron D; Haran TE
    Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2305713120. PubMed ID: 38015851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic reconstruction of a functional transcriptional regulatory network.
    Hu Z; Killion PJ; Iyer VR
    Nat Genet; 2007 May; 39(5):683-7. PubMed ID: 17417638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.